Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.

SE, Nissen; SJ, Nicholls; K, Wolski; R, Nesto; S, Kupfer; A, Perez; H, Jure; Larochellière R, De; CS, Staniloae; K, Mavromatis; J, Saw; B, Hu; AM, Lincoff; EM, Tuzcu

doi:10.1001/jama.299.13.1561

Public

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.

Shared by NobleBlocks on Mar 31, 2008 • 12:00 AM UTC

Authors:

Nissen SE

Nicholls SJ

Wolski K

Abstract

Context No antidiabetic regimen has demonstrated the ability to reduce progression of coronary atherosclerosis. Commonly used oral glucose-lowering agents include sulfonylureas, which are insulin secretagogues, and thiazolidinediones, which are insulin sensitizers.Objective To compare the effects of...

Discussions